ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST) Research

Based in Horsholm, Denmark, ExpreS2ion Biotech Holding AB, along with its subsidiary ExpreS2ion Biotechnologies, specializes in creating and manufacturing complex proteins for use in vaccines and diagnostic products. The company's development pipeline includes a capsid virus-like particle COVID-19 vaccine, an influenza vaccine, and a breast cancer vaccine, all of which are currently undergoing Phase II clinical trials. ExpreS2ion is also engaged in developing a malaria vaccine. Furthermore, the company extends its reach by licensing its proprietary ExpreS2 platform to various research organizations and pharmaceutical businesses. ExpreS2ion Biotech Holding AB commenced operations in 2015.

Open ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.